| 22-803 |
Virentem Ventures, LLC v. Google LLC |
Federal Circuit |
2023-02-24 |
Denied |
Response Waived |
claim-construction due-process federal-circuit patent patent-invalidity ptab ptab-determination rule-36 |
Does the Federal Circuit's use of Rule 36 to affirm without opinion PTAB invalidity determinations that are challenged based on pure questions of law … |
| 22-544 |
Innovation Sciences, LLC v. Amazon.com, Inc., et al. |
Federal Circuit |
2022-12-14 |
Denied |
Response Waived |
35-usc-102 anticipation anticipatory-reference clear-and-convincing clear-and-convincing-evidence invention patent patent-infringement patent-invalidity prior-art |
Whether an inference that a device that could have existed before the invention thereof by an inventor is properly treated as an anticipatory referenc… |
| 21-1458 |
EPA Drug Initiative II v. Hikma Pharmaceuticals USA Inc., et al. |
Federal Circuit |
2022-05-18 |
Denied |
Response Waived |
appellate-review fraud-on-court fraud-on-the-court hazel-atlas-doctrine hazel-atlas-glass-co-v-hartford-empire-co judicial-proceedings patent-invalidation patent-invalidity standing supervisory-power third-party-intervention |
Questions presented |
| 20-440 |
Minerva Surgical, Inc. v. Hologic, Inc., et al. |
Federal Circuit |
2020-10-06 |
Judgment Issued |
Amici (12)Relisted (2) |
35-usc-282 assignor-estoppel due-process judicial-doctrine patent patent-infringement patent-invalidity patent-law statutory-interpretation |
Whether a defendant in a patent infringement action who assigned the patent, or is in privity with an assignor of the patent, may have a defense of in… |
| 19-101 |
Imperium IP Holdings (Cayman), Ltd. v. Samsung Electronics Co., Ltd., et al. |
Federal Circuit |
2019-07-19 |
Denied |
Amici (2)Response Waived |
appellate-review burden-of-proof credibility-determinations credibility-of-witnesses expert-testimony jury-trial jury-trial-rights jury-verdict patent-infringement patent-invalidity patent-validity seventh-amendment standard-of-review |
Whether an appellate court may reverse a jury verdict based on its own view that expert testimony was credible, 'unrebutted,' and 'uncontradicted,' or… |
| 18-1397 |
Prism Technologies LLC v. Sprint Spectrum L.P., dba Sprint PCS |
Federal Circuit |
2019-05-06 |
Denied |
Response Waived |
35-usc-101 appellate-jurisdiction collateral-estoppel federal-circuit federal-circuit-jurisdiction jurisdiction-scope mandate-rule patent-claims patent-eligibility patent-invalidity retroactive-expansion |
Whether the Federal Circuit Court of Appeals may retroactively expand the scope of its appellate jurisdiction to invalidate patent claims under 35 U.S… |
| 18-823 |
ZUP, LLC v. Nash Manufacturing, Inc. |
Federal Circuit |
2018-12-28 |
Denied |
Amici (1)Response Waived |
invention invention-evaluation legal-analysis long-felt-need non-obviousness obviousness obviousness-standard patent patent-invalidity patent-law prima-facie prior-art rebuttal secondary-considerations |
Whether evidence of 'secondary considerations' is less important in rebutting prima facie evidence of obviousness |
| 18-190 |
Queen's University at Kingston v. Samsung Electronics Co., Ltd., et al. |
Federal Circuit |
2018-08-13 |
Denied |
Response Waived |
administrative-procedure-act burden-of-proof due-process enablement inter-partes-review patent-invalidity prior-art |
Does the Federal Circuit's requirement that patent owners negate enablement of prior art in the first instance invert the statutory burden of proving … |
| 18-182 |
AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc., et al. |
Federal Circuit |
2018-08-09 |
Denied |
Response Waived |
actual-controversy article-iii declaratory-judgment drug-exclusivity fda-approval generic-drugs patent-invalidity pharmaceutical pharmaceutical-patents standing |
Whether the 'actual controversy' requirement of the Declaratory Judgment Act requires a party seeking to introduce a generic drug product to file an a… |